跳至主要内容
临床试验/NCT06010992
NCT06010992招募中2 期

A Clinical Study Evaluating the Potential Benefit of Nitazoxanide in Patients With Type 2 Diabetes Mellitus

Tanta University2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2023年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
70
试验地点
2
主要终点
Glycemic control

研究概览

简要总结

Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. Despite the advancement in anti-diabetic drug therapy, most patients fail to achieve optimal glycemic control. This highlights the need for more effective strategies to control type 2 diabetes mellitus.

Nitazoxanide (NTZ), a broad-spectrum anti-infective drug with activity against various protozoa, helminthes, bacteria, and viruses, was identified as peroxisome proliferative activated receptor gamma (PPARγ) agonist using one dimensional drug profile matching. Additionally, it improved insulin sensitivity in insulin-resistant type 2 diabetic rats. Therefore, this study is designed to evaluate the efficacy of nitazoxanide as adjunctive therapy in patients with type 2 diabetes mellitus.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Glycated hemoglobin (HbA1c) between 7% and 9%.
  • Body mass index ≥ 25 kg/m2

排除标准

  • Pregnant or nursing women.
  • Type 1 diabetes mellitus.
  • Liver disease (alanine aminotransferase > 3 upper normal limit).
  • Kidney disease (estimated glomerular filtration rate < 60 ml/min/1.73 m2).
  • Inflammatory bowel diseases.
  • History of allergy and/or adverse reactions to the drugs used in the study.

研究组 & 干预措施

Group 2

Experimental

35 Patients with type 2 diabetes receiving nitazoxanide 500 mg orally twice daily in addition to metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors (such as vildagliptin).

干预措施: Nitazoxanide (Drug)

结局指标

主要结局

Glycemic control

时间窗: 12 weeks

Fasting blood glucose and glycated hemoglobin

次要结局

  • Serum levels of asprosin(12 weeks)
  • Insulin resistance(12 weeks)
  • Lipid profile(12 weeks)
  • Serum levels of A-kinase anchoring protein 1(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Eman Ghonaim

Assistant lecturer

Tanta University

研究点 (2)

Loading locations...

相似试验